BioXcel Therapeutics Inc BTAI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation
-
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
-
BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
-
BioXcel Therapeutics Reports Second Quarter 2024 Financial Results
-
BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024
-
BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film
-
BioXcel Therapeutics Shares Rise Premarket on FDA Fast-Track Designation
-
BioXcel Therapeutics Shares Sink After Weak 3Q
Trading Information
- Previous Close Price
- $0.53
- Day Range
- $0.51–0.54
- 52-Week Range
- $0.51–5.62
- Bid/Ask
- $0.52 / $0.55
- Market Cap
- $21.77 Mil
- Volume/Avg
- 955,752 / 635,189
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.11
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company’s commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 74
Comparables
Valuation
|
Metric
|
BTAI
|
BIVI
|
MORF
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 0.39 | 4.62 |
Price/Sales | 7.11 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BTAI
|
BIVI
|
MORF
|
|---|---|---|---|
Quick Ratio | 2.09 | 2.43 | 23.71 |
Current Ratio | 2.35 | 2.45 | 24.13 |
Interest Coverage | −6.97 | −9.50 | — |
Quick Ratio
BTAI
BIVI
MORF
Profitability
|
Metric
|
BTAI
|
BIVI
|
MORF
|
|---|---|---|---|
Return on Assets (Normalized) | −111.36% | −115.58% | −20.07% |
Return on Equity (Normalized) | — | −256.00% | −20.72% |
Return on Invested Capital (Normalized) | −173.85% | −130.07% | −24.50% |
Return on Assets
BTAI
BIVI
MORF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Rhwrrfyfd | Qtndk | $566.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Csfqttq | Spcmr | $119.2 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fktzsgb | Nkskvq | $113.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Jqfvmxtlf | Vjmlbkv | $35.0 Bil | |||
| argenx SE ADR
ARGX
| Cyffvkqwh | Bjvc | $32.5 Bil | |||
| BioNTech SE ADR
BNTX
| Dpdlndlx | Wrkn | $27.5 Bil | |||
| Moderna Inc
MRNA
| Rpzgqqlm | Zgqp | $24.5 Bil | |||
| United Therapeutics Corp
UTHR
| Ghqkymmt | Ysw | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Qkxcmgnl | Jqgjwp | $13.1 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Yglxwjmry | Tgzzxw | $12.4 Bil |
United States